A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare two different approaches to treating non-small cell
lung cancer (NSCLC) in East Asian never-smoker participants. Half of the participants will
receive chemotherapy (pemetrexed/cisplatin) followed by an oral anti-cancer agent (gefitinib)
and the other half of the participants will receive only the oral anti-cancer agent
(gefitinib).